| [1] |
Fleischmann C, Reichert F, Cassini A, et al. Global incidence and mortality of neonatal sepsis: a systematic review and Meta-analysis[J]. Arch Dis Child, 2021, 106(8): 745-752. DOI: 10.1136/archdischild-2020-320217.
|
| [2] |
Iba T, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation[J]. Anesthesiology, 2020, 132(5): 1238-1245. DOI: 10.1097/aln.0000000000003122.
|
| [3] |
Gialamprinou D, Mitsiakos G, Katsaras GN, et al. Neonatal sepsis and hemostasis[J]. Diagnostics (Basel), 2022, 12(2): 261. DOI: 10.3390/diagnostics12020261.
|
| [4] |
Go H, Ohto H, Nollet KE, et al. Risk factors and treatments for disseminated intravascular coagulation in neonates[J]. Ital J Pediatr, 2020, 46(1): 54. DOI: 10.1186/s13052-020-0815-7.
|
| [5] |
Haidl H, Zöhrer E, Pohl S, et al. New insights into neonatal coagulation: normal clot formation despite lower intra-clot thrombin levels[J]. Pediatr Res, 2019, 86(6): 719-724. DOI: 10.1038/s41390-019-0531-4.
|
| [6] |
Iba T, Connors JM, Nagaoka I, et al. Recent advances in the research and management of sepsis-associated DIC[J]. Int J Hematol, 2021, 113(1): 24-33. DOI: 10.1007/s12185-020-03053-y.
|
| [7] |
Gando S, Fujishima S, Saitoh D, et al. The significance of disseminated intravascular coagulation on multiple organ dysfunction during the early stage of acute respiratory distress syndrome[J]. Thromb Res, 2020, 191: 15-21. DOI: 10.1016/j.thromres.2020.03.023.
|
| [8] |
O′reilly D, Murphy CA, Drew R, et al. Platelets in pediatric and neonatal sepsis: novel mediators of the inflammatory cascade[J]. Pediatr Res, 2022, 91(2): 359-367. DOI: 10.1038/s41390-021-01715-z.
|
| [9] |
Sudhakar B, Kusuma S, Karunakar G, et al. Role of platelet count and indices in the diagnosis of neonatal sepsis[J]. J Dr NTR Univ Health Sci, 2022, 11(3): 233-236. DOI: 10.4103/jdrntruhs.jdrntruhs_112_22.
|
| [10] |
Yang YC, Mao J. Value of platelet count in the early diagnosis of nosocomial invasive fungal infections in premature infants[J]. Platelets, 2018, 29(1): 65-70. DOI: 10.1080/09537104.2017.1293810.
|
| [11] |
Levi M, Vincent JL, Tanaka K, et al. Effect of a recombinant human soluble thrombomodulin on baseline coagulation biomarker levels and mortality outcome in patients with sepsis-associated coagulopathy[J]. Crit Care Med, 2020, 48(8): 1140-1147. DOI: 10.1097/ccm.0000000000004426.
|
| [12] |
Iba T, Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis[J]. J Thromb Haemost, 2018, 16(2): 231-241. DOI: 10.1111/jth.13911.
|
| [13] |
Hsieh LT, Santos SJD, Hall BS, et al. Aberrant stromal tissue factor localisation and mycolactone-driven vascular dysfunction, exacerbated by IL-1β，are linked to fibrin formation in Buruli ulcer lesions[J]. PLoS Pathog, 2022, 18(1): e1010280. DOI: 10.1371/journal.ppat.1010280.
|
| [14] |
Zelaya H, Rothmeier AS, Ruf W. Tissue factor at the crossroad of coagulation and cell signaling[J]. J Thromb Haemost, 2018, 16(10): 1941-1952. DOI: 10.1111/jth.14246.
|
| [15] |
|
| [16] |
Grover SP, Mackman N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis[J]. Arterioscler Thromb Vasc Biol, 2018, 38(4): 709-725. DOI: 10.1161/ATVBAHA.117.309846.
|
| [17] |
Takashi I, Midori K, Ikuro M. Endotheliopathy in septic conditions: mechanistic insight into intravascular coagulation[J]. Crit Care, 2021, 25(1): 95. DOI: 10.1186/s13054-021-03524-6.
|
| [18] |
|
| [19] |
|
| [20] |
Formoso VRY, Mota RB, Soares H, et al. Developmental hemostasis in the neonatal period[J]. World J Pediatr, 2022, 18(1): 7-15. DOI: 10.1007/s12519-021-00492-3.
|
| [21] |
Schupp T, Weidner K, Rusnak J, et al. Diagnostic and prognostic significance of the prothrombin time/international normalized ratio in sepsis and septic shock[J]. Clin Appl Thromb Hemost, 2022, 28. DOI: 10.1177/10760296221137893.
|
| [22] |
|
| [23] |
Zhang J, Xue M, Chen Y, et al. Identification of soluble thrombomodulin and tissue plasminogen activator-inhibitor complex as biomarkers for prognosis and early evaluation of septic shock and sepsis-induced disseminated intravascular coagulation[J]. Ann Palliat Med, 2021, 10(10): 10170-10184. DOI: 10.21037/apm-21-2222.
|
| [24] |
|
| [25] |
Piliponsky AM, Shubin NJ, Lahiri AK, et al. Basophil-derived tumor necrosis factor can enhance survival in a sepsis model in mice[J]. Nat Immunol, 2019, 20(2): 129-140. DOI: 10.1038/s41590-018-0288-7.
|
| [26] |
|
| [27] |
Sullivan BA, Fairchild KD. Vital signs as physiomarkers of neonatal sepsis[J]. Pediatr Res, 2022, 91(2): 273-282. DOI: 10.1038/s41390-021-01709-x.
|
| [28] |
Giri SHN, Aman AK, Hanafie A. Hemostasis changes and its relationship with SOFA score in sepsis patients[J]. Bali Med J, 2019, 8(2): 587. DOI: 10.15562/bmj.v8i2.1409.
|
| [29] |
Li J, Zhou J, Ren H, et al. Clinical efficacy of soluble thrombomodulin, tissue plasminogen activator inhibitor complex, thrombin-antithrombin complex, α2-plasmininhibitor-plasmin complex in pediatric sepsis[J]. Clin Appl Thromb Hemost, 2022, 28: 10760296221102929. DOI: 10.1177/10760296221102929.
|
| [30] |
Hasuike Y, Kakita N, Aichi M, et al. Imbalance of coagulation and fibrinolysis can predict vascular access failure in patients on hemodialysis after vascular access intervention[J]. J Vasc Surg, 2019, 69(1): 174.e2-180.e2. DOI: 10.1016/j.jvs.2018.04.029.
|
| [31] |
Martin-Fernandez M, Vaquero-Roncero LM, Almansa R, et al. Endothelial dysfunction is an early indicator of sepsis and neutrophil degranulation of septic shock in surgical patients[J]. BJS Open, 2020, 4(3): 524-534. DOI: 10.1002/bjs5.50265.
|
| [32] |
|
| [33] |
Zhong L, Dou J, Lin Q, et al. Tissue-type plasminogen activator-inhibitor complex as an early predictor of septic shock: a retrospective, single-center study[J]. Dis Markers, 2022, 2022: 9364037. DOI: 10.1155/2022/9364037.
|
| [34] |
Leong R, Patel J, Samji N, et al. Use of thrombolytic agents to treat neonatal thrombosis in clinical practice[J]. Blood Coagul Fibrinolysis, 2022, 33(4): 193-200. DOI: 10.1097/mbc.0000000000001134.
|
| [35] |
Kurimoto T, Shimoji Y, Shimabukuro A, et al. Recombinant tissue-type plasminogen activator treatment in an extremely low birth weight infant[J]. Clin Case Rep, 2021, 9(5): e04236. DOI: 10.1002/ccr3.4236.
|
| [36] |
Cabrera-Garcia D, Miltiades A, Parsons SM, et al. High levels of plasminogen activator inhibitor-1, tissue plasminogen activator and fibrinogen in patients with severe COVID-19[J]. Cold Spring Harbor Lab Press, 2021. DOI: 10.1101/2020.12.29.20248869.
|
| [37] |
Dastgheib SA, Najafi F, Shajari A, et al. Association of plasminogen activator inhibitor-1 4G5G polymorphism with risk of diabetic nephropathy and retinopathy：？a systematic review and Meta-analysis[J]. J Diabetes Metab Disord, 2020, 19(2): 2005-2016. DOI: 10.1007/s40200-020-00675-1.
|
| [38] |
Denorme F, Rustad JL, Portier I, et al. Neutrophil extracellular trap inhibition improves survival in neonatal mouse infectious peritonitis[J]. Pediatr Res, 2023, 93(4): 862-869. DOI: 10.1038/s41390-022-02219-0.
|
| [39] |
|
| [40] |
Uchimido R, Schmidt EP, Shapiro NI. The glycocalyx: a novel diagnostic and therapeutic target in sepsis[J]. Crit Care, 2019, 23(1): 16. DOI: 10.1186/s13054-018-2292-6.
|
| [41] |
Fernández-Sarmiento J, Molina CF, Salazar-Pelaez LM, et al. Biomarkers of glycocalyx injury and endothelial activation are associated with clinical outcomes in patients with sepsis: a systematic review and Meta-analysis[J]. J Intensive Care Med, 2023, 38(1): 95-105. DOI: 10.1177/08850666221109186.
|
| [42] |
Puchwein-Schwepcke A, Genzel-Boroviczény O, Nussbaum C. The endothelial glycocalyx: physiology and pathology in neonates, infants and children[J]. Front Cell Dev Biol, 2021, 9: 733557. DOI: 10.3389/fcell.2021.733557.
|
| [43] |
Ahlam F, Wiam S, Jesús B, et al. The endothelial glycocalyx and neonatal sepsis[J]. Int J Mol Sci, 2022, 24(1): 364. DOI: 10.3390/ijms24010364.
|
| [44] |
Resch E, Hinkas O, Urlesberger B, et al. Neonatal thrombocytopenia-causes and outcomes following platelet transfusions[J]. Eur J Pediatr, 2018, 177(7): 1045-1052. DOI: 10.1007/s00431-018-3153-7.
|
| [45] |
Patel RM, Josephson C. Neonatal and pediatric platelet transfusions: current concepts and controversies[J]. Curr Opin Hematol, 2019, 26(6): 466-472. DOI: 10.1097/moh.0000000000000542.
|
| [46] |
Ferrer-Marín F, Sola-Visner M. Neonatal platelet physiology and implications for transfusion[J]. Platelets, 2022, 33(1): 14-22. DOI: 10.1080/09537104.2021.1962837.
|
| [47] |
Vanvooren DM, Bradshaw WT, Blake SM. Disseminated Intravascular coagulation in the neonate[J]. Neonatal Netw, 2018, 37(4): 205-211. DOI: 10.1891/0730-0832.37.4.205.
|
| [48] |
Mitsiakos G, Karametou M, Gkampeta A, et al. Effectiveness and safety of 4-factor prothrombin complex concentrate (4PCC) in neonates with intractable bleeding or severe coagulation disturbances: a retrospective study of 37 cases[J]. J Pediatr Hematol Oncol, 2019, 41(3): e135-e140. DOI: 10.1097/mph.0000000000001397.
|
| [49] |
Warren BB, Moyer GC, Manco-Johnson MJ. Hemostasis in the pregnant woman, the placenta, the fetus, and the newborn infant[J]. Semin Thromb Hemost, 2023, 49(4): 319-329. DOI: 10.1055/s-0042-1760332.
|
| [50] |
Hamadah HK, Kabbani MS. Local pulmonary administration of factor VIIa (rFVIIa) in massive pulmonary haemorrhage in post-operative cardiac infant[J]. Cardiol Young, 2023, 33(5): 835-837. DOI: 10.1017/s1047951122003006.
|
| [51] |
Gunel Karaburun IE, Kayki G, Aytac SS, et al. Transplacental hemophilia A and prophylactic treatment with intravenous immunoglobulin and recombinant factor Ⅶa in the newborn period: a case report[J]. Blood Coagul Fibrinolysis, 2021, 32(2): 151-154. DOI: 10.1097/mbc.0000000000000978.
|
| [52] |
Conti GO, Molinari AC, Signorelli SS, et al. Neonatal systemic thrombosis: an updated overview[J]. Curr Vasc Pharmacol, 2018, 16(5): 499-509. DOI: 10.2174/1570161116666180117101445.
|
| [53] |
Kenet G, Cohen O, Bajorat T, et al. Insights into neonatal thrombosis[J]. Thromb Res, 2019, 181(Suppl 1): S33-S36. DOI: 10.1016/s0049-3848(19)30364-0.
|
| [54] |
Ozment CP, Scott BL, Bembea MM, et al. Anticoagulation and transfusion management during neonatal and pediatric extracorporeal membrane oxygenation: a survey of medical directors in the united states[J]. Pediatr Crit Care Med, 2021, 22(6): 530-541. DOI: 10.1097/pcc.0000000000002696.
|
| [55] |
Moiseiwitsch N, Brown AC. Neonatal coagulopathies: a review of established and emerging treatments[J]. Exp Biol Med (Maywood), 2021, 246(12): 1447-1457. DOI: 10.1177/15353702211006046.
|
| [56] |
Li B, Saka R, Takama Y, et al. Recombinant human soluble thrombomodulin reduces the severity and incidence of necrotizing enterocolitis in a newborn rat model[J]. Surg Today, 2019, 49(11): 971-976. DOI: 10.1007/s00595-019-01832-7.
|
| [57] |
Ashina M, Fujioka K, Nishida K, et al. Recombinant human thrombomodulin attenuated sepsis severity in a non-surgical preterm mouse model[J]. Sci Rep, 2020, 10(1): 333. DOI: 10.1038/s41598-019-57265-2.
|